Articles related to IMMUNOTHERAPY

From JAMA Network Open comes this conclusion: “In this study, the benefit associated with olaparib was reduced, eliminated, or inferior in specific subgroups of patients when treatment outcomes were compared with a more active standard of care, ie, cabazitaxel. While treatment with olaparib was associated with superior rPFS in patients with BRCA1/2 variants, those with other HRR variants may have worse outcomes with this approach, which should be reassessed by national guidelines. Numerous active studies…will add to the data regarding the role of PARP inhibitors in mCRPC.”

The results, presented during the virtual ESMO Congress 2021, will substantially change the population of patients with melanoma who undergo treatment in the adjuvant setting, according to Jason J. Luke, MD: “Patients with stage IIB/C melanoma have similar rates of recurrence and melanoma specific survival to those with stage IIIA/B disease. Despite this, adjuvant anti-PD-1 immunotherapy has only been available in standard practice for stage III disease. The results of KEYNOTE-716 will facilitate access to anti-PD-1 for stage IIB/C patients and, in a sense, level the playing field against melanoma.”

Lead author of the study, Dr. Ana Maria Arance, who presented the results over the summer at the ASCO Annual Meeting, commented: “With additional follow-up, lenvatinib plus pembrolizumab continues to show clinically meaningful, durable responses in patients with advanced melanoma with confirmed progression on a PD-1 or PD-L1 inhibitor given alone or in combination. These data support lenvatinib plus pembrolizumab as a potential regimen for this population of high unmet need.”

Second-line therapy with pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) is a highly effective and well-tolerated regimen that can efficiently bridge patients with rel/ref cHL to high-dose therapy and autologous hematopoietic cell transplantation (HDT/AHCT).

The encouraging results of the phase 3 ORIENT-11 trial, which included 397 patients with previously untreated, locally advanced metastatic non-squamous NSCLC without sensitizing EGFR or ALK aberrations, were published in the Journal of Thoracic Oncology.

The case reported is based on a 53-year-old woman who presented to her gastroenterologist with symptoms of bowel obstruction and right upper quadrant pain. Based on her age and excellent performance status, aggressive treatment with a triplet chemotherapy regimen of oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin (FOLFOXIRI) in combination with the anti–vascular endothelial growth factor receptor antibody bevacizumab was begun.